SARS-CoV-2 serology increases diagnostic accuracy in CT-suspected, PCR-negative COVID-19 patients during pandemic.
Adolescent
Adult
Aged
Aged, 80 and over
Algorithms
COVID-19
/ blood
Critical Care
/ statistics & numerical data
Female
Hospitalization
/ statistics & numerical data
Humans
Immunoglobulin G
/ analysis
Immunoglobulin M
/ analysis
Male
Middle Aged
Pandemics
Polymerase Chain Reaction
Retrospective Studies
Seroconversion
Serologic Tests
Tomography, X-Ray Computed
Young Adult
Accuracy
COVID-19
Computed tomography
Efficacy
SARS-CoV-2
Serology
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
23 Apr 2021
23 Apr 2021
Historique:
received:
29
07
2020
accepted:
14
04
2021
entrez:
24
4
2021
pubmed:
25
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
In the absence of PCR detection of SARS-CoV-2 RNA, accurate diagnosis of COVID-19 is challenging. Low-dose computed tomography (CT) detects pulmonary infiltrates with high sensitivity, but findings may be non-specific. This study assesses the diagnostic value of SARS-CoV-2 serology for patients with distinct CT features but negative PCR. IgM/IgG chemiluminescent immunoassay was performed for 107 patients with confirmed (group A: PCR + ; CT ±) and 46 patients with suspected (group B: repetitive PCR-; CT +) COVID-19, admitted to a German university hospital during the pandemic's first wave. A standardized, in-house CT classification of radiological signs of a viral pneumonia was used to assess the probability of COVID-19. Seroconversion rates (SR) determined on day 5, 10, 15, 20 and 25 after symptom onset (SO) were 8%, 25%, 65%, 76% and 91% for group A, and 0%, 10%, 19%, 37% and 46% for group B, respectively; (p < 0.01). Compared to hospitalized patients with a non-complicated course (non-ICU patients), seroconversion tended to occur at lower frequency and delayed in patients on intensive care units. SR of patients with CT findings classified as high certainty for COVID-19 were 8%, 22%, 68%, 79% and 93% in group A, compared with 0%, 15%, 28%, 50% and 50% in group B (p < 0.01). SARS-CoV-2 serology established a definite diagnosis in 12/46 group B patients. In 88% (8/9) of patients with negative serology > 14 days after symptom onset (group B), clinico-radiological consensus reassessment revealed probable diagnoses other than COVID-19. Sensitivity of SARS-CoV-2 serology was superior to PCR > 17d after symptom onset. Approximately one-third of patients with distinct COVID-19 CT findings are tested negative for SARS-CoV-2 RNA by PCR rendering correct diagnosis difficult. Implementation of SARS-CoV-2 serology testing alongside current CT/PCR-based diagnostic algorithms improves discrimination between COVID-19-related and non-related pulmonary infiltrates in PCR negative patients. However, sensitivity of SARS-CoV-2 serology strongly depends on the time of testing and becomes superior to PCR after the 2
Sections du résumé
BACKGROUND
BACKGROUND
In the absence of PCR detection of SARS-CoV-2 RNA, accurate diagnosis of COVID-19 is challenging. Low-dose computed tomography (CT) detects pulmonary infiltrates with high sensitivity, but findings may be non-specific. This study assesses the diagnostic value of SARS-CoV-2 serology for patients with distinct CT features but negative PCR.
METHODS
METHODS
IgM/IgG chemiluminescent immunoassay was performed for 107 patients with confirmed (group A: PCR + ; CT ±) and 46 patients with suspected (group B: repetitive PCR-; CT +) COVID-19, admitted to a German university hospital during the pandemic's first wave. A standardized, in-house CT classification of radiological signs of a viral pneumonia was used to assess the probability of COVID-19.
RESULTS
RESULTS
Seroconversion rates (SR) determined on day 5, 10, 15, 20 and 25 after symptom onset (SO) were 8%, 25%, 65%, 76% and 91% for group A, and 0%, 10%, 19%, 37% and 46% for group B, respectively; (p < 0.01). Compared to hospitalized patients with a non-complicated course (non-ICU patients), seroconversion tended to occur at lower frequency and delayed in patients on intensive care units. SR of patients with CT findings classified as high certainty for COVID-19 were 8%, 22%, 68%, 79% and 93% in group A, compared with 0%, 15%, 28%, 50% and 50% in group B (p < 0.01). SARS-CoV-2 serology established a definite diagnosis in 12/46 group B patients. In 88% (8/9) of patients with negative serology > 14 days after symptom onset (group B), clinico-radiological consensus reassessment revealed probable diagnoses other than COVID-19. Sensitivity of SARS-CoV-2 serology was superior to PCR > 17d after symptom onset.
CONCLUSIONS
CONCLUSIONS
Approximately one-third of patients with distinct COVID-19 CT findings are tested negative for SARS-CoV-2 RNA by PCR rendering correct diagnosis difficult. Implementation of SARS-CoV-2 serology testing alongside current CT/PCR-based diagnostic algorithms improves discrimination between COVID-19-related and non-related pulmonary infiltrates in PCR negative patients. However, sensitivity of SARS-CoV-2 serology strongly depends on the time of testing and becomes superior to PCR after the 2
Identifiants
pubmed: 33892720
doi: 10.1186/s12931-021-01717-9
pii: 10.1186/s12931-021-01717-9
pmc: PMC8062836
doi:
Substances chimiques
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119Références
Expert Rev Mol Diagn. 2020 May;20(5):453-454
pubmed: 32297805
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Jpn J Radiol. 2020 May;38(5):409-410
pubmed: 32266524
Lancet Respir Med. 2020 Mar;8(3):e11-e12
pubmed: 32061335
J Thorac Imaging. 2010 Feb;25(1):68-75
pubmed: 20160606
Clin Microbiol Infect. 2009 Dec;15(12):1053-66
pubmed: 19929972
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
Intensive Care Med. 2020 Sep;46(9):1781-1783
pubmed: 32572527
Clin Infect Dis. 2020 Nov 19;71(16):2255-2258
pubmed: 32337590
J Hosp Infect. 2020 Jun;105(2):113-115
pubmed: 32294511
Clin Chem Lab Med. 2020 Jun 25;58(7):1070-1076
pubmed: 32172228
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Emerg Microbes Infect. 2020 Dec;9(1):940-948
pubmed: 32357808
J Infect. 2020 May;80(5):e1-e6
pubmed: 32171869
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Sci Total Environ. 2020 Jul 10;725:138539
pubmed: 32304973